Oncos Therapeutics presenting at BIO Equity Europe 2010 in Zurich on May 19-20
Meet Oncos Therapeutics in Zurich at BIO Equity Europe 2010, presenting on May 19 at 5:30pm.
Oncos Therapeutics develops new cancer therapies based on its next generation oncolytic viruses. The company’s unique Advanced Therapy Access Program was started in 2007 for cancer patients in whom standard-of-care therapies have failed. Today, over 200 patients have undergone individually tailored oncolytic virus therapy suggesting strong safety and efficacy. The program is based on scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development. Oncos Therapeutics publishes industry’s oncolytic virus blog: www.oncolyticvirus.wordpress.com.
Participating conference’s Next Wave Companies session, Timo Ahopelto, VP Strategy, from Oncos Therapeutics will discuss company’s Advanced Therapy Access Program, and especially the latest safety and efficacy findings with a special focus on breast cancer.
